Objective: To evaluate the accuracy of integrated FDG-PET/CT and tumor markers for the depiction of recurrent ovarian carcinoma.
Methods: Patients with pathologically proven ovarian cancer, who underwent cytoreductive surgery and 3-6 cycles of adjuvant chemotherapy, were included in this study. They all underwent a thorough physical examination, tumor marker determination, and FDG-PET/CT imaging. The sensitivity, specificity, accuracy, and positive and negative predictive values for the tumor detection with PET/CT versus different tumor markers were performed in relation to the results at histological analysis after second-look surgery or clinical follow-up.
Results: A total of 37 patients underwent FDG-PET/CT scans. Among them, 22 patients underwent exploratory laparotomy and 15 had diagnostic laparoscopy. Overall, 24 patients were documented to have ovarian cancer recurrence after second operation. FDG-PET/CT had sensitivity, specificity, accuracy, and positive and negative predictive values of 100, 85, 94, 92, and 100%, respectively.
Conclusion: Our study has shown that PET/CT is a sensitive tool to assist in the early identification and recurrent ovarian cancer, amenable to secondary cytoreduction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00404-010-1404-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
B7-H3 (CD276), a member of the B7-family of immune checkpoint proteins, has been shown to have immunological and non-immunological effects promoting tumorigenesis [1, 2] and expression correlates with poor prognosis for many solid tumors, including cervical, ovarian and breast cancers [3-6]. We recently identified a tumor-cell autochthonous tumorigenic role for dimerization of the 4Ig isoform of B7-H3 (4Ig-B7-H3) [7], where 4Ig-B7-H3 dimerization activated tumor-intrinsic cellular proliferation and tumorigenesis pathways, providing a novel opportunity for therapeutic intervention. Herein, a live cell split-luciferase complementation strategy was used to visualize 4Ig-B7-H3 homodimerization in a high-throughput small molecule screen (HTS) to identify modulators of this protein-protein interaction (PPI).
View Article and Find Full Text PDFLiposomal doxorubicin (Dox), a treatment option for recurrent ovarian cancer, often suffers from suboptimal biodistribution and efficacy, which might be addressed with precision drug delivery systems. Here, we introduce a catheter-based endoscopic probe designed for multispectral, quantitative monitoring of light-triggered drug release. This tool utilizes red-light photosensitive porphyrin-phospholipid (PoP), which is encapsulated in liposome bilayers to enhance targeted drug delivery.
View Article and Find Full Text PDFEnhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment.
Front Immunol
December 2024
Leeds Institute of Medical Research, School of Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Background: There has been limited success of cancer immunotherapies in the treatment of ovarian cancer (OvCa) to date, largely due to the immunosuppressive tumour microenvironment (TME). Tumour-associated macrophages (TAMs) are a major component of both the primary tumour and malignant ascites, promoting tumour growth, angiogenesis, metastasis, chemotherapy resistance and immunosuppression. Differential microRNA (miRNA) profiles have been implicated in the plasticity of TAMs.
View Article and Find Full Text PDFThe role of tribbles homolog 2 in cell proliferation.
Cell Commun Signal
January 2025
School of Medicine, Southeast University, Nanjing, Jiangsu, China.
Tribbles homolog 2 (TRIB2), a pseudoserine/threonine kinase, is a member of the TRIB family. TRIB2 primarily regulates cell proliferation through its scaffold or adaptor effect on promoting the degradation of target proteins by E3 ligase-dependent ubiquitination and regulating mitogen-activated protein kinase (MAPK) and protein kinase B (AKT) signaling pathways. TRIB2 is not only involved in the physiological proliferation of cells (granulosa cells, myoblasts, naive T cells, and thymocytes) during normal development but also in the pathological proliferation of vascular smooth muscle cells and a variety of cancer cells (lung cancer cells, liver cancer cells, leukemia cells, pancreatic cancer cells, gastric cancer cells, prostate cancer cells, thyroid cancer cells, cervical cancer cells, melanoma cells, colorectal cancer cells, ovarian cancer cells and osteosarcoma cells) under disease conditions.
View Article and Find Full Text PDFPromising new drugs and therapeutic approaches for treatment of ovarian cancer-targeting the hallmarks of cancer.
BMC Med
January 2025
Department of Gynaecology and Obstetrics, University and University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany.
Ovarian cancer remains the most lethal gynecological malignancy. Despite the approval of promising targeted therapy such as bevacizumab and PARP inhibitors, 5-year survival has not improved significantly. Thus, there is an urgent need for new therapeutics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!